CareLit · DOI-Nachweis · Pneumologie
Case report from a study investigating everolimus combined with paclitaxel and carboplatin in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC)
DOI 10.1055/s-0035-1544662
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Steins, W Engel-Riedel, C Grohé, C Kropf-Sanchen, J von Pawel, S Gütz, J Kollmeier, W Eberhardt, D Ukena, I Nimmrich, C Weiß, M Potzner, M Serke, M Thomas
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Targeted therapies are discussed as an approach to improve outcome in neuroendocrine tumors of the lung. With current treatment options like platinum derivates and etoposide, large cell neuroendocrine carcinoma of the lung (LCNEC) patients have a poor prognosis. Everolimus (RAD001) is an inhibitor of mTOR, a component of the PI3K/AKT/mTOR pathway known to be dysregulated in neuroendocrine tumors (NETs). In the prese…
Zitieren
Zitierempfehlung
M Steins, W Engel-Riedel, C Grohé, C Kropf-Sanchen, J von Pawel, S Gütz, J Kollmeier, W Eberhardt, D Ukena, I Nimmrich, C Weiß, M Potzner, M Serke, M Thomas (2015) Case report from a study investigating everolimus combined with paclitaxel and carboplatin in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC). Pneumologie (02). https://doi.org/10.1055/s-0035-1544662
Mit CareLit weiterarbeiten